Yi‐Zhou Jiang

9.5k citations

167 papers · 5.9k indexed · 7 hit papers · h-index 40

Impact in

Cancer Research top 0.5%
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis

Papers in

Cancer Research 75
- Cancer Genomics and Diagnostics 26
- Breast Cancer Treatment Studies 20
Oncology 72
- Cancer Immunotherapy and Biomarkers 26
- HER2/EGFR in Cancer Research 16

Co-authors: Song‐Yang Wu Tong‐Ming Fu Zhi-Ming ShaoYi XiaoDing Ma Zhi‐Ming Shao Xi Jin Da‐Qiang Li
Journals: Cancer Research (10 papers)Cell Research (5 papers)Cancer Biology and Medicine (5 papers)Advanced Science (5 papers)Med (4 papers)
Partner nations: China United States Macao

In The Last Decade

Yi‐Zhou Jiang

157 papers receiving 5.9k citations

Hit Papers

7 papers align trajectories log scale

Advances in targeting histone deacetylase for treatment of solid tumors 2024 · 56 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 Journal of Hematology & Oncology
2023 Cell Metabolism
2022 Cell Metabolism
2022 Cell Research
2021 Journal of Hematology & Oncology
2020 Cell Metabolism
2020 Molecular Cancer

Peers

Countries citing papers authored by Yi‐Zhou Jiang

Since Specialization

Citations

This map shows the geographic impact of Yi‐Zhou Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi‐Zhou Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi‐Zhou Jiang more than expected).

Fields of papers citing papers by Yi‐Zhou Jiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yi‐Zhou Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi‐Zhou Jiang. The network helps show where Yi‐Zhou Jiang may publish in the future.

Co-authors

The 25 scholars most cited alongside Yi‐Zhou Jiang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yi‐Zhou Jiang Line = papers co-authored together Yi‐Zhou Jiang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer Cancer Research ·Xiu-Zhi Zhu, Hu-Yun-Long Zhang, Yi-Fan Zhou, Yi-Yu Chen, Tong Fu, Ming-Liang Jin, Ya-Xin Zhao, Yi-Fan Xie, Xiaohua Zeng, Xi Jin, Yi‐Zhou Jiang, Zhi‐Ming Shao	2025	0
2	Interferon-induced senescent CD8 ⁺ T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer Science Translational Medicine ·Tong Fu, Xi Jin, Min He, Yi-Yu Chen, Yun‐Song Yang, Li Chen, Hu-Yun-Long Zhang, Lei Fan, Jiong Wu, Zhonghua Wang, Yiwei Chu, Ronghua Liu, Yi‐Zhou Jiang, Zhi‐Ming Shao	2025	2
3	Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial Nature Medicine ·Songyang Wu, Xi Jin, Yin Liu, Zi-Yu Wang, Wen‐Jia Zuo, Ding Ma, Yi Xiao, Tong‐Ming Fu, Yu-Ling Xiao, Li Chen, Xiyu Liu, Lei Fan, Zhonghua Wang, Minhong Shen, Ronghua Liu, Wen-Jun Chai, Zhi‐Ming Shao, Yi‐Zhou Jiang	2025	3
4	A Dynamic Contrast‐Enhanced MRI‐Based Vision Transformer Model for Distinguishing HER2‐Zero, ‐Low, and ‐Positive Expression in Breast Cancer and Exploring Model Interpretability Advanced Science ·Xu Zhang, Yiyuan Shen, Guanhua Su, Yuan Guo, Rencheng Zheng, Siyao Du, Si‐Yi Chen, Yi Xiao, Zhi‐Ming Shao, Lina Zhang, He Wang, Yi‐Zhou Jiang, Yajia Gu, Chao You	2025	0
5	Oxidized cellulose microneedle patch combined with vascular embolization and local delivery of timolol maleate for hemangiomas Colloids and Surfaces B Biointerfaces ·Hua Jiang, Yiqun Guo, Xiaoyun Tan, Yi‐Zhou Jiang, Ningdong Pang, Chuanqiang Niu, Lang Liu, Zijun Zhou, Lu Liu, Haibo Li	2024	3
6	The HLA-I landscape confers prognosis and antitumor immunity in breast cancer Briefings in Bioinformatics ·Xiao-Hong Ding, Yi Xiao, Fenfang Chen, Chenglin Liu, Tong‐Ming Fu, Zhi‐Ming Shao, Yi‐Zhou Jiang	2024	5
7	Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial Cell Research ·Yin Liu, Xiu-Zhi Zhu, Yi Xiao, Song‐Yang Wu, Wen‐Jia Zuo, Qiang Yu, A‐Yong Cao, Junjie Li, Ke‐Da Yu, Guang‐Yu Liu, Jiong Wu, Tao Sun, Jiuwei Cui, Zheng Lv, Huiping Li, Xiaoyu Zhu, Yi‐Zhou Jiang, Zhonghua Wang, Zhi‐Ming Shao	2023	39
8	Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria Cell Research ·Xiaoqing Xie, Yi Yang, Qiang Wang, Hao-Fei Liu, Xuanyu Fang, Chenglong Li, Yi‐Zhou Jiang, Shuai Wang, Hongyu Zhao, Jingya Miao, Shuaishuai Ding, Xindong Liu, Xiaohong Yao, Wentao Yang, Jun Jiang, Zhi-Ming Shao, Guoxiang Jin, Xiu‐Wu Bian	2023	66
9	Molecular classification of hormone receptor-positive HER2-negative breast cancer Nature Genetics ·Xi Jin, Yi-Fan Zhou, Ding Ma, Shen Zhao, Cai‐Jin Lin, Yi Xiao, Tong‐Ming Fu, Chenglin Liu, Yiyu Chen, Wen-Xuan Xiao, Yaqing Liu, Qingwang Chen, Ying Yu, Leming Shi, Jinxiu Shi, Wei Huang, John F. R. Robertson, Yi‐Zhou Jiang, Zhi‐Ming Shao	2023	54
10	Deep learning framework for comprehensive molecular and prognostic stratifications of triple-negative breast cancer Fundamental Research ·Shen Zhao, Chaoyang Yan, Hong Lv, Jingcheng Yang, Chao You, Ziang Li, Ding Ma, Yi Xiao, Jia Hu, Wentao Yang, Yi‐Zhou Jiang, Jun Xu, Zhi‐Ming Shao	2022	14
11	A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers Scientific Data ·Qingwang Chen, Yaqing Liu, Yuechen Gao, Ruolan Zhang, Wanwan Hou, Zehui Cao, Yi‐Zhou Jiang, Yuanting Zheng, Leming Shi, Ding Ma, Jingcheng Yang, Zhi‐Ming Shao, Ying Yu	2022	14
12	Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer Cell Reports ·Tianqi Gong, Yi‐Zhou Jiang, Chen Shao, Wenting Peng, Mingwei Liu, Da‐Qiang Li, Ben-Yu Zhang, Peng Du, Yin Huang, Feifei Li, Muyun Li, Zhao-Lian Han, Xi Jin, Ding Ma, Yi Xiao, Pengyuan Yang, Jun Qin, Zhi‐Ming Shao, Weimin Zhu	2022	37
13	PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer Cancer Research ·Tian‐Jian Yu, Yingying Liu, Xiaoguang Li, Bi Lian, Xun‐Xi Lu, Xi Jin, Zhi‐Ming Shao, Xin Hu, Gen‐Hong Di, Yi‐Zhou Jiang	2021	32
14	MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer Journal for ImmunoTherapy of Cancer ·Siyu Wu, Yi Xiao, Jinli Wei, Xiao‐En Xu, Xi Jin, Xin Hu, Da‐Qiang Li, Yi‐Zhou Jiang, Zhi-Ming Shao	2021	62
15	Making ERRFI1-Derived Peptides ‘Bindable’ to the Allosteric Dimerization Interface of Breast Cancer ERBB3 Kinase by Adding a Nonbonded Interaction System International Journal of Peptide Research and Therapeutics ·Chenghong Ji, Jianmin Zhuang, Yi‐Zhou Jiang, Jiangang Mu, Longhai Lin, Chen Yide	2021	1
16	Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer Nature Cancer ·Minhong Shen, Heath A. Smith, Yong Wei, Yi‐Zhou Jiang, Sheng Zhao, Nicole Wang, Michelle Rowicki, Yong Tang, Xiang Hang, Song‐Yang Wu, Liling Wan, Zhi‐Ming Shao, Yibin Kang	2021	45
17	Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer JNCI Journal of the National Cancer Institute ·Ding Ma, Siyu Chen, Jin-Xiao Ren, Yu‐Chen Pei, Congwei Jiang, Shen Zhao, Yi Xiao, Xiao‐En Xu, Guang‐Yu Liu, Xin Hu, Xiaozhen Liang, Ke‐Da Yu, Da‐Qiang Li, Yi‐Zhou Jiang, Zhi‐Ming Shao	2020	28
18	Integration of whole‐genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple‐negative breast cancer International Journal of Cancer ·Guangdong Xie, Haiyuan Yang, Ding Ma, Yihua Sun, Haiquan Chen, Xin Hu, Yi‐Zhou Jiang, Zhi‐Ming Shao	2019	15
19	Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer Clinical Cancer Research ·Yi Xiao, Ding Ma, Shen Zhao, Chen Suo, Jinxiu Shi, Mengzhu Xue, Miao Ruan, Hai Wang, Jingjing Zhao, Qin Li, Peng Wang, Leming Shi, Wentao Yang, Wei Huang, Xin Hu, Ke‐Da Yu, Shenglin Huang, François Bertucci, Yi‐Zhou Jiang, Zhi-Ming Shao	2019	265
20	Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting SHILAP Revista de lepidopterología ·Zhen Wu, Xu S, Lixia Zhou, Wei Yin, Yuan Lin, Yanjun Du, Yang Wang, Yi‐Zhou Jiang, Yin K, John H. Zhang, Jianwei Lu	2018	2

About Yi‐Zhou Jiang

Yi‐Zhou Jiang is a scholar working on Cancer Research, Oncology, Biological Psychiatry, Immunology and Aging, having authored 167 papers that have together received 5.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (26 papers), Cancer Genomics and Diagnostics (26 papers), Breast Cancer Treatment Studies (20 papers), RNA modifications and cancer (17 papers), HER2/EGFR in Cancer Research (16 papers), Advanced Breast Cancer Therapies (16 papers), Immunotherapy and Immune Responses (12 papers) and Ferroptosis and cancer prognosis (11 papers). The work is most often cited by research in Cancer Research (2.1k citations), Oncology (2.0k citations), Immunology (1.2k citations), Molecular Biology (2.8k citations) and Pulmonary and Respiratory Medicine (1.2k citations). Yi‐Zhou Jiang has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Song‐Yang Wu, Tong‐Ming Fu, Zhi-Ming Shao, Yi Xiao, Ding Ma, Zhi‐Ming Shao, Xi Jin, Da‐Qiang Li, Zhi‐Ming Shao and Ding Ma. Their work appears in journals such as Cancer Research, Cell Research, Cancer Biology and Medicine, Advanced Science and Med.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact